Tributary Capital Management LLC increased its position in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 121.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,390 shares of the biopharmaceutical company’s stock after purchasing an additional 6,790 shares during the period. Tributary Capital Management LLC’s holdings in Intercept Pharmaceuticals were worth $1,535,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of the stock. Raymond James Trust N.A. purchased a new stake in Intercept Pharmaceuticals in the fourth quarter worth $278,000. Kistler Tiffany Companies LLC grew its stake in shares of Intercept Pharmaceuticals by 33.3% in the fourth quarter. Kistler Tiffany Companies LLC now owns 400 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 100 shares during the last quarter. Metropolitan Life Insurance Co NY grew its stake in shares of Intercept Pharmaceuticals by 13.2% in the third quarter. Metropolitan Life Insurance Co NY now owns 8,113 shares of the biopharmaceutical company’s stock worth $538,000 after acquiring an additional 943 shares during the last quarter. Man Group plc grew its stake in shares of Intercept Pharmaceuticals by 396.2% in the third quarter. Man Group plc now owns 35,688 shares of the biopharmaceutical company’s stock worth $2,368,000 after acquiring an additional 28,496 shares during the last quarter. Finally, Orbimed Advisors LLC purchased a new stake in shares of Intercept Pharmaceuticals in the third quarter worth $2,137,000. 79.22% of the stock is currently owned by institutional investors.
Intercept Pharmaceuticals stock opened at $110.25 on Friday. The company has a debt-to-equity ratio of 4.02, a current ratio of 5.49 and a quick ratio of 5.49. Intercept Pharmaceuticals Inc has a one year low of $56.76 and a one year high of $131.87. The stock has a market capitalization of $3.69 billion, a PE ratio of -10.15 and a beta of 1.50. The business’s fifty day moving average is $116.27 and its 200 day moving average is $81.58.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($2.59) EPS for the quarter, missing the consensus estimate of ($2.35) by ($0.24). Intercept Pharmaceuticals had a negative net margin of 143.09% and a negative return on equity of 495.47%. The business had revenue of $61.95 million for the quarter, compared to analysts’ expectations of $63.89 million. During the same period last year, the business earned ($2.18) earnings per share. The company’s quarterly revenue was up 31.8% on a year-over-year basis. As a group, sell-side analysts expect that Intercept Pharmaceuticals Inc will post -10.3 EPS for the current fiscal year.
In related news, CEO Mark Pruzanski sold 35,437 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $100.00, for a total transaction of $3,543,700.00. Following the sale, the chief executive officer now directly owns 469,165 shares of the company’s stock, valued at $46,916,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Lisa Bright sold 595 shares of the stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $75.00, for a total value of $44,625.00. Following the sale, the insider now directly owns 18,732 shares in the company, valued at $1,404,900. The disclosure for this sale can be found here. Insiders have sold 58,810 shares of company stock worth $5,702,623 over the last ninety days. 5.00% of the stock is currently owned by insiders.
A number of equities research analysts have recently commented on the company. B. Riley increased their target price on Intercept Pharmaceuticals from $133.00 to $158.00 and gave the stock a “buy” rating in a research note on Thursday, January 9th. Wells Fargo & Co reissued an “overweight” rating and issued a $146.00 target price (up from $120.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, December 17th. Citigroup cut Intercept Pharmaceuticals from a “buy” rating to a “neutral” rating and increased their target price for the stock from $85.00 to $140.00 in a research note on Thursday, January 2nd. Robert W. Baird reissued a “buy” rating and issued a $227.00 target price on shares of Intercept Pharmaceuticals in a research note on Tuesday, December 17th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $150.00 target price on shares of Intercept Pharmaceuticals in a research note on Tuesday, December 17th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $141.65.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Featured Article: Hedge Funds Explained
Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals Inc (NASDAQ:ICPT).
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.